Abstract:Mesenchymal stromal stem cells (MSCs) possess a remarkable potential for numerous clinical applications due to their unique properties including self-renewal, immunomodulation, paracrine actions and multilineage differentiation. However, the translation of MSC-based Advanced Therapy Medicinal Products (ATMPs) into the clinic has frequently met with inconsistent outcomes. One of the suspected reasons for this issue is the inherent and extensive variability that exists among such ATMPs, which makes the interpretation of their clinical efficacy difficult to assess, as well as to compare the results of various studies. This variability stems from numerous reasons including differences in tissue sources, donor attributes, variances in manufacturing protocols, as well as modes of administration. MSCs can be isolated from various tissues including bone marrow, umbilical cord, adipose tissue and others, each with its unique phenotypic and functional characteristics. While MSCs from different sources do share common features, they also exhibit distinct gene expression profiles and functional properites. Donor-specific factors such as age, sex, body mass index, and underlying health conditions can influence MSC phenotype, morphology, differentiation potential and function. Moreover, variations in preparation of MSC products introduces additional heterogeneity as a result of cell culture media composition, presence or absence of added growth factors, use of different serum supplements and culturing techniques. Once MSC products are formulated, storage protocols play a pivotal role in its efficacy. Factors that affect cell viability include cell concentration, delivery solution and importantly, post-thawing protocols where applicable. Ensuing, differences in administration protocols can critically affect the distribution and functionallity of administered cells. As MSC-based therapies continue to advance through numerous clinical trials, implication of strategies to reduce product heterogeneity is imperative. Central to addressing these challenges is the need for precise prediction of clinical responses, which require well-defined MSC populations and harmonized assessment of their specific functions. By addressing these issues by meaningful approaches, such as, e.g., MSC pooling, the field can overcome barriers to advance towards more consistent and effective MSC-based therapies.

The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy

Heterogeneity of mesenchymal stem cells: characterization and application in cell therapy

Cause and consequence of heterogeneity in human mesenchymal stem cells: Challenges in clinical application

Strategies to address mesenchymal stem/stromal cell heterogeneity in immunomodulatory profiles to improve cell-based therapies

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

Heterogeneity of mesenchymal stem cells in cartilage regeneration: from characterization to application

Functional Heterogeneity of Bone Marrow Mesenchymal Stem Cell Subpopulations in Physiology and Pathology

MSCs: Biological Characteristics, Clinical Applications and Their Outstanding Concerns

Mesenchymal Stem Cells: a New Trend for Cell Therapy

Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities

Mesenchymal stem cells: Cell therapy and regeneration potential

Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations

Mesenchymal Stem Cell Spheroids: Potential Cell Materials for Cell Therapy

The issue of heterogeneity of MSC-based advanced therapy medicinal products–a review

Odontogenic MSC Heterogeneity: Challenges and Opportunities for Regenerative Medicine

Mesenchymal stem cells biological and biotechnological advances: Implications for clinical applications

Challenges and Controversies in Human Mesenchymal Stem Cell Therapy

Sorting Technology for Mesenchymal Stem Cells from a Single Tissue Source

Multiple Dimensions of Using Mesenchymal Stem Cells for Treating Liver Diseases: from Bench to Beside.

Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease

Mesenchymal Stem Cell Subpopulations: Phenotype, Property and Therapeutic Potential.